Presage Biosciences secures investment from Takeda; no terms disclosed

20 August 2015

Privately held Presage Biosciences on Thursday said it has secured an investment from Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) without disclosing any terms.

The company focussed on cancer research said it has been working in collaboration with the Takeda for the past three years to identify and develop new drug combinations by utilizing its handheld microinjection device called CIVO, technology.

Graeme Martin, chief executive of Takeda Ventures, said: “Presage’s CIVO technology holds promise to better translate preclinical discoveries to patients, particularly in the field of novel cancer drug combinations.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK